

MANAGEMENT OF DELIRIUM
AT THE END OF LIFE –
DEVELOPING AN EVIDENCE
BASE

Meera Agar

MBBS, MPC, FACHPM, FRACP

A thesis submitted for the degree of Doctor of Philosophy

2013

Discipline of Palliative and Supportive Care

School of Medicine

Faculty of Health Sciences

Flinders University, Adelaide, South Australia

Table of contents

List of figures	xv
Glossary	xvii
Abstract	xxii
Chapter 1: Introduction	1
1.1 Definitions	1
1.2 Historical development of the classification systems of delirium	2
1.3 Nosology of delirium	5
1.3.1 People without cancer	11
1.3.2 People with cancer	14
1.4 Delirium phenomenology	15
1.4.1 Psychomotor subtypes of delirium	15
1.4.1.1 What are the pathophysiological correlates and clinical outcomes associated with psychomotor subtype	19
1.4.1.2 Studies of delirium subtypes in cancer and palliative care	21
1.5 Subsyndromal and persistent delirium	23
1.5.1 Subsyndromal delirium	23
1.5.2 Persistent delirium	25
1.6 Epidemiology of delirium in cancer populations	26
1.7 Clinical measurement of delirium	31
1.7.1 Clinical measures of cognitive function	32
1.7.2 Clinical delirium diagnostic instruments	39
1.7.2.1 Memorial Delirium Assessment Scale	39
1.7.2.2 Delirium Rating Scale and Delirium Rating Scale – Revised-98	40
1.7.3 Pain assessment in the delirious patient	51
1.8 Risk factors and precipitants	52
1.8.1 Psychoactive medications as a risk factor for delirium	57
1.8.2 Opioids as a risk factor for delirium	59
1.8.3 Uncontrolled pain as a risk for delirium	61
1.8.4 Interaction between pain and delirium pathophysiology	61
1.9 Reversibility in cancer and palliative populations	62
1.10 Current hypotheses of the pathophysiology of delirium	65

1.11	Cholinergic mechanisms in delirium	69
1.11.1	Concept of anticholinergic load	69
1.11.2	Methods to calculate anticholinergic medication burden	70
1.11.3	Serum measures of anticholinergic activity	74
1.12	Clinical studies of anticholinergic load	76
1.12.1	Clinical studies of anticholinergic medication burden	76
1.12.2	Clinical studies of serum anticholinergic activity	78
1.13	Impact of delirium	96
1.13.1	Mortality	96
1.13.2	Patient and caregiver experience	99
1.14	Delirium management in clinical practice	107
1.14.1	Pharmacological treatment of delirium in palliative care and cancer populations	108
1.14.2	Management of pain in the patient with delirium and the role of opioid rotation	116
1.14.3	Non-pharmacological management of delirium	117
1.14.4	Delirium prevention	121
1.14.5	Challenges of delirium detection and management in practice	122
1.15	Summary	124
1.16	Outline of thesis content	124
Chapter 2: Delirium management by medical specialists in advanced cancer		126
2.1	Current delirium practices	126
2.2	Methods	134
2.2.1	Participants	134
2.2.2	Aims	136
2.2.3	Questionnaire	136
2.2.4	Ethical approval	137
2.2.5	Statistical analysis	137
2.3	Results	138
2.3.1	Piloting of survey	138
2.3.2	Response rate	138
2.3.3	Demographics of respondents	138
2.3.4	Location of care	139
2.3.5	Investigative approaches	145
2.3.6	Management approaches	146
2.3.6.1	Pre-emptive treatments prior to delirium aetiology being known	146
2.3.6.2	Pharmacological management	146
2.3.6.3	Choice of pharmacological agent by symptom	146

2.3.6.4	Dosing of pharmacological agents	153
2.3.6.5	Non-pharmacological approaches	156
2.3.6.6	How do we know treatment has been successful?	156
2.3.6.6.1	Clinical outcomes in delirium in the setting of good functional status	156
2.3.6.6.2	Clinical outcomes in delirium superimposed on the last days of life	158
2.3.6.6.3	Frequency of reversible component to delirium	158
2.3.6.6.4	Indicators of a poor outcome	159
2.3.6.7	Reported routine use of a delirium or cognitive assessment	160
2.4	Discussion	160
2.4.1	Key findings	160
2.4.2	What do these data support or refute?	161
2.4.2.1	Location of care	161
2.4.2.2	Investigative approaches	164
2.4.2.3	Symptom control differences: pharmacological and non-pharmacological approaches	166
2.4.3	Limitations of the study	173
2.4.4	Implications for practice	174
2.4.5	Implications for research	176
2.5	Conclusion	177
Chapter 3: Making decisions about delirium—a nursing perspective		178
3.1	Background	178
3.2	Methods	181
3.2.1	Design	181
3.2.2	Theoretical framework for the methodology	182
3.2.3	Setting	182
3.2.3.1	Characteristics of the inpatient units	182
3.2.3.2	Rationale for choice of inpatient settings	183
3.2.4	Participants	183
3.2.5	Semi-structured interviews	184
3.2.5.1	Characteristics of the interviewers	184
3.2.5.2	Characteristics of the interview	185
3.2.5.3	Analysis	185
3.3	Findings	186
3.3.1	Demographics of participants	186
3.3.2	Themes	189
3.3.2.1	Superficial recognition and understanding of delirium as a syndrome	191
3.3.2.1.1	Limited definitions	191
3.3.2.1.2	Behavioural and cognitive symptoms	192
3.3.2.1.3	Symptoms infrequently identified	193
3.3.2.2	Nursing assessment—use of an investigative compared to a problem solving approach	193

3.3.2.2.1	Precipitants related to specialty area	193
3.3.2.2.2	Concept of reversibility and irreversibility	195
3.3.2.2.3	Investigative assessment compared to assessment of a shortlist of problems	196
3.3.2.2.4	Continuous assessment of risk	197
3.3.2.3	Distress and the effect on others	198
3.3.2.3.1	Specific situations related to patient distress	198
3.3.2.3.2	Family distress	198
3.3.2.3.3	Distress of other patients in the unit	199
3.3.2.3.4	Staff frustration of barriers to quality care	199
3.3.2.3.5	Staff distress and exhaustion	199
3.3.2.4	Management—maintaining dignity and minimising chaos	201
3.3.2.4.1	High levels of confidence in delirium management in the face of limited understanding of delirium	201
3.3.2.4.2	Multiple decisions and actions	201
3.3.2.4.3	Variable views on medication choices	202
3.3.2.4.4	Diverse non-pharmacological strategies are highly valued	205
3.3.2.4.5	Conflicting opinions about physical restraints	207
3.3.2.4.6	Experiential learning and senior role models guide management	207
3.4	Discussion	208
3.4.1	Recognising delirium	209
3.4.2	Baseline vulnerability and precipitants	210
3.4.3	Assessment	211
3.4.4	Impact of delirium	211
3.4.5	Non-pharmacological strategies	213
3.4.6	Pharmacological strategies	214
3.4.7	Reported confidence and knowledge	216
3.4.8	Decision-making in nursing practice	216
3.4.9	Strengths of this study	218
3.4.10	Limitations of this study	219
3.4.11	Future directions for practice	219
3.4.12	Future directions for research	220
3.4.13	Comparison of findings from nursing practice to medical specialist practice	221
Chapter 4:	Anticholinergic load from regular prescribed medications in palliative care	223
4.1	Methods to assess the potential for adverse medication effects	223
4.2	Clinical utility of methods to assess potential for adverse medication effects	225
4.3	The importance of medication with anticholinergic action	227
4.4	What is known about the potential risk of adverse medication effects in palliative care?	228

4.5	Methods	230
4.5.1	Setting	230
4.5.2	Study design	231
4.5.2.1	Methodology of the Palliative Care Trial	231
4.5.2.2	Methodology of the main study and sub-study	232
4.5.2.2.1	Participants for the main study	232
4.5.2.2.2	Participants for the sub-study	232
4.5.3	Ethics approval	233
4.5.4	Assessments	233
4.5.5	Data collection	233
4.5.5.1	Demographic and baseline clinical data	233
4.5.5.2	Medication use	233
4.5.5.3	Medications with anticholinergic action	234
4.5.5.4	Quality of life	234
4.5.5.5	Performance status	235
4.5.5.6	Symptom assessment	236
4.5.5.7	Health-service utilisation	236
4.5.5.8	Survival	237
4.5.6	Data analysis	237
4.5.6.1	Quality of life, performance status and symptoms	237
4.5.6.2	Health-service utilisation and survival	238
4.6	Results	239
4.6.1	Participants of the Palliative Care Trial	239
4.6.2	Comparison of the Palliative Care Trial patient population with Southern Adelaide Palliative Services referrals during the same time period	241
4.6.3	Participants in the main study	241
4.6.4	Participants in the sub-study	243
4.6.4.1	Total anticholinergic score as death approaches	246
4.6.4.2	Total anticholinergic score classified by 'reason for prescription' as death approaches	247
4.6.4.3	Association of total anticholinergic score with Australia – modified Karnofsky Performance Scale and quality of life	251
4.6.4.4	Total anticholinergic score and symptoms	252
4.6.4.5	Baseline Australia-modified Karnofsky Performance Scale and total anticholinergic score at first visit	252
4.6.4.6	Association between health-service utilisation and total anticholinergic scores	253
4.6.4.7	Survival times	254
4.7	Discussion	255
4.7.1	New findings from this study	255
4.7.2	What other data do these findings support or refute?	257
4.7.2.1	Association with physical and cognitive function impairments	258
4.7.2.2	Associations when anticholinergic load is considered in conjunction with sedative medication	261
4.7.2.3	Association with self-reported symptoms	261
4.7.2.4	Association with delirium	262

4.7.2.5	Association with health-service utilisation and mortality	263
4.7.3	What are the implications for prescribing?	268
4.7.4	Strengths of this study	270
4.7.5	Innovations in this analysis	270
4.7.6	Limitations of this study	271
4.7.6.1	Limitations of the sample	271
4.7.6.2	Limitations of the measures	272
4.7.7	Generalisability	274
4.7.8	Future directions for research, practice and policy	275

Chapter 5: Serum anticholinergic activity and delirium in advanced cancer 277

5.1 Pathophysiological abnormalities in delirium 277

5.1.1	Serum marker of anticholinergic activity	279
5.1.2	Serum anticholinergic activity and delirium	279
5.1.3	Calculated anticholinergic load of medication	280
5.1.4	Correlation of serum anticholinergic activity with calculated anticholinergic load of medication	280

5.2 Aims 281

5.3 Objectives and methods 281

5.3.1	Primary objective	281
5.3.2	Secondary objectives	282
5.3.3	Exploratory objectives	282
5.3.4	Study design	282
5.3.5	Study setting	282
5.3.6	Patient population	283
5.3.6.1	Inclusion criteria	283
5.3.6.2	Exclusion criteria	284
5.3.7	Consent procedures	284
5.3.8	Study procedures	286
5.3.8.1	Performance status and functional status	287
5.3.8.1.1	Australia-Modified Karnofsky Performance Status	287
5.3.8.1.2	Barthel Index	287
5.3.8.2	Assessment of comorbidities	287
5.3.8.2.1	The Cumulative Illness Rating Scale	287
5.3.8.2.2	Charlson Comorbidity index	288
5.3.8.3	Medication assessment and clinician rated anticholinergic scale calculation	288
5.3.9	Serum anticholinergic level assay	290
5.3.10	Delirium diagnosis – Memorial Delirium Assessment Scale	292
5.3.11	Aetiological factors	294
5.3.12	Outcomes	294
5.3.13	Study flow	295
5.3.14	Data collection schedule	296

5.4	Statistical considerations	297
5.4.1	Sample size	297
5.4.2	Descriptive statistics	297
5.4.3	Univariate analyses	297
5.4.4	Correlation between serum anticholinergic activity at baseline	298
5.4.5	Linear mixed models: longitudinal analysis over time of association between serum anticholinergic activity and Memorial Delirium Assessment Scale	298
5.4.6	Logistic regression and receiver operator curve for predictive ability of baseline serum anticholinergic activity and delirium occurrence	300
5.4.7	Generalised estimating equations to determine clinical variables at baseline which were predictive of Memorial Delirium Assessment Scale scores during admission	300
5.4.8	Surrogate markers of serum anticholinergic activity	301
5.4.9	Survival time and serum anticholinergic activity	301
5.4.10	Summary of analyses	302
5.5	Results	305
5.5.1	Participants	305
5.5.2	Memorial Delirium Assessment Scale total score at baseline	309
5.5.3	Serum anticholinergic activity at baseline	309
5.5.4	Association between serum anticholinergic activity and Clinician Rated Anticholinergic Scale-modified version at baseline	310
5.5.5	Association of serum anticholinergic activity and Memorial Delirium Assessment Scale at baseline	311
5.5.6	Association between serum anticholinergic activity and oral morphine equivalents, oral diazepam equivalents, oral morphine equivalents at baseline	312
5.5.7	Memorial Delirium Assessment Scale scores over time	315
5.5.8	Longitudinal association between serum anticholinergic activity and Memorial Delirium Assessment Scale	317
5.5.9	Episodes of delirium	323
5.5.10	Serum anticholinergic activity at baseline compared to delirium occurrence	324
5.5.11	Predictive ability of serum anticholinergic activity for occurrence of delirium	326
5.5.11.1	Regression analyses with Memorial Delirium Assessment Scale as a continuous outcome	327
5.5.12	Potential clinical factors which could act as surrogate markers of serum anticholinergic activity	329
5.5.13	Survival	329
5.5.14	Outcomes	332
5.5.15	Other analyses	333
5.6	Discussion	333
5.6.1	Results of primary analysis	333
5.6.2	Results of exploratory analyses	335
5.6.3	What other data do these findings support or refute?	335
5.6.3.1	How does serum anticholinergic activity levels in advanced cancer compare with levels reported in the literature	335

5.6.3.2	Comparison with recent studies exploring the association of serum anticholinergic activity with delirium	337
5.6.4	Hypotheses of contributing factors to measured serum anticholinergic activity and reasons for lack of association with calculated anticholinergic load	340
5.6.5	Strengths of this study	342
5.6.6	Limitations of this study	342
5.6.6.1	Limitations of the assay	343
5.6.6.2	Limitations of methods and sample	344
5.6.7	Generalisability	345
5.6.8	Future directions for research, practice and policy	345

Chapter 6: Risperidone and haloperidol for delirium 347

6.1 Background and rationale 347

6.1.1	Pathophysiological abnormalities in delirium and rationale for intervention	347
6.1.2	Existing evidence for pharmacological management of delirium	348
6.1.3	Studies of risperidone for delirium	349
6.1.4	Aims	355

6.2 Study objectives and hypothesis 356

6.2.1	Primary objective	356
6.2.2	Secondary objectives	356
6.2.2.1	Efficacy	356
6.2.2.2	Toxicity	357
6.2.2.3	Pathophysiology	357
6.2.2.4	Health outcomes and health services utilisation	357
6.2.3	Primary null hypothesis	358
6.2.4	Secondary null hypotheses	358

6.3 Study population 358

6.3.1	Inclusion criteria	358
6.3.2	Exclusion criteria	359

6.4 Study methods 359

6.4.1	Overall study design	359
6.4.2	Treatment arms	360
6.4.3	Study medication	361
6.4.4	Dosing schedule	362
6.4.5	Dose schedule timeline	363
6.4.6	Method of assigning participants to treatment groups	365
6.4.7	Blinding	365
6.4.8	Method of administration	366
6.4.9	Drug accountability	366
6.4.10	Drug supply	366
6.4.11	Drug destruction	367
6.4.12	Concurrent treatments	367

6.4.13	Rescue medications	367
6.4.14	Uncontrolled delirium symptoms	368
6.4.15	Specific adverse effects	369
6.4.16	Dose modification	369
6.4.17	Treatment failure	370
6.4.18	Cessation for reasons other than treatment failure	370
6.4.19	Post study treatments	370
6.5	Outcomes and measures	371
6.5.1	Primary outcome and measure	371
6.5.2	Secondary outcomes	371
6.5.2.1	Efficacy outcomes	371
6.5.2.2	Toxicity outcomes	372
6.5.3	Health-service utilisation and long-term outcomes	372
6.5.4	Serum apoptosis marker levels	372
6.5.5	Laboratory measures	373
6.5.5.1	Metabolic factors	373
6.5.5.2	Serum apoptosis markers	373
6.5.6	Medical and physical measurements	374
6.5.7	Demographics and clinical information	377
6.5.7.1	Performance status	377
6.5.7.2	Barthel Index	377
6.5.7.3	Comorbidity burden	377
6.5.7.4	Vulnerability factors	378
6.5.7.5	Precipitating factors	378
6.5.7.6	Medication	379
6.5.8	Nursing Delirium Screening Scale	380
6.5.9	Memorial Delirium Assessment Scale	381
6.5.10	Extrapyramidal symptom rating scale	381
6.5.11	Sedation (Richmond Agitation Sedation Scale)	382
6.5.12	Prior cognition impairment – Informant Questionnaire on Cognitive Decline in the elderly	382
6.5.13	Mini-Mental Status Examination	383
6.5.14	Patient, caregiver and nurse distress - Delirium Experience Questionnaire	383
6.5.15	Quality of life	383
6.5.16	Assessments for economic analysis	384
6.5.17	Consent process	385
6.5.17.1	Proxy consent	385
6.5.17.2	Consent for serum sample	386
6.5.17.3	Nurse and caregiver consent	386
6.5.17.4	Participant consent	386
6.6	Reporting of adverse events	387
6.6.1	Unblinding	388
6.6.2	Data Safety Monitoring Board	388
6.7	Analysis plan	389

6.7.1	Primary endpoint	389
6.7.2	Analysis of primary null hypothesis	389
6.7.3	Analysis of secondary null hypotheses	389
6.7.4	Analysis of toxicity outcomes	389
6.7.5	Analysis of other efficacy outcomes	390
6.7.6	Time-to-event analysis	390
6.7.7	Linear mixed models	390
6.7.8	Power and sample size	390
6.7.9	Economic analyses	390
6.8	Study progress and results to date	392
6.8.1	Ethical review	392
6.8.2	Recruitment and completion	393
6.8.3	Participant characteristics at baseline	398
6.8.4	Serious adverse events	401
6.9	Discussion	401
6.9.1	Design considerations	402
6.9.1.1	Inclusion and exclusion criteria	402
6.9.1.2	Choice of primary outcome	404
6.9.1.3	Power and sample size	406
6.9.1.4	Choice of three arm study	407
6.9.1.5	Study intervention and comparator	408
6.9.1.6	Choice of secondary outcomes	411
6.9.1.7	Other considerations for the statistical analysis	412
6.9.1.8	Safety monitoring	413
6.9.2	Recruitment	414
6.9.2.1	Project recruitment	414
6.9.2.2	Actual recruitment	415
6.9.3	Consent	416
6.9.3.1	Advanced consent	416
6.9.3.2	Proxy consent	416
6.10	Conclusions	419
Chapter 7:	Conclusion	420
7.1	Clinical decision-making	420
7.2	Anticholinergic mechanisms: implications for delirium risk and prescribing	421
7.3	Clinical trial design	423
Appendices		426
References		486

List of tables

Chapter 1

- Table 1 Comparison of classifications of delirium
- Table 2 DSM-IV-R criteria for delirium due to a general medical condition
- Table 3 Prevalence and incidence of delirium in cancer patients
- Table 4 Delirium measurement instruments – cognitive testing
- Table 5 Delirium diagnostic instruments
- Table 6 Delirium numeric rating scales
- Table 7 Studies exploring risk factors for delirium in cancer and palliative populations
- Table 8 Summary of studies exploring association of opioids as a class or individual opioids with delirium
- Table 9 Studies of serum anticholinergic levels and delirium
- Table 10 Studies of serum anticholinergic levels and anticholinergic use or cognitive change
- Table 11 Range of serum anticholinergic activity in different studies
- Table 12 Open label studies of antipsychotics in cancer and palliative care populations
- Table 13 Randomised controlled studies of antipsychotics in cancer and palliative care populations
- Table 14 Non-pharmacological therapy for delirium

Chapter 2

- Table 15 Differences in patient populations by specialty
- Table 16 Two contrasting vignettes of delirium
- Table 17 Percentage of specialists cross-tabulated for choices in care for Vignette 1
- Table 18 Logistic regression analysis of predictors of choice of care at home for Vignette 1
- Table 19 Percentage of specialists cross-tabulated for choices in care for Vignette 2
- Table 20 Specific choices of pharmacological agents by symptom and specialty (Vignette 1)
- Table 21 Usefulness of specific agents to manage delirium symptoms by specialty group
- Table 22 Dosing ranges by agent and specialty group for Vignette 1
- Table 23 Dosing ranges by agent and specialty group for Vignette 2
- Table 24 Treatment response used by each specialty in Vignette 1
- Table 25 Clinical indicators of treatment success used by each specialty in Vignette 2
- Table 26 Frequency of reversible component to delirium
- Table 27 Predictors of poor outcome used by each specialty

Chapter 3

Table 28 Demographics of the participants

Table 29 Outline of themes and subthemes

Chapter 4

Table 30 Baseline demographic and clinical characteristics for all Palliative Care Trial patient participants

Table 31 Baseline demographic and clinical characteristics for Palliative Care Trial participants with cancer and substudy participants

Table 33 Contribution of symptom specific drugs to anticholinergic load at last assessment

Table 34 Contribution of medication for comorbid disease to anticholinergic load at last assessment

Table 35 Associations with total anticholinergic load: functional status, quality of life and symptoms

Table 36 Baseline total anticholinergic score and Australian-modified Karnofsky Performance Status at first visit where status was less than 60

Chapter 5

Table 37 Conversion factors to oral morphine equivalents

Table 38 Conversion factors for oral diazepam equivalents

Table 39 Data collection schedule

Table 40 Summary of bivariate analyses

Table 41 Summary of multivariate analyses

Table 42 Baseline demographics and clinical characteristics of all participants

Table 43 Baseline clinical characteristics of participants by delirium category

Table 44 Predicted multiplicative changes in Memorial Delirium Assessment Scale score for a one-unit increase in serum anticholinergic activity

Table 45 Effect of including possible confounding factors as main effects in the model

Table 46 Spearman correlations on Day 0, by Australia-modified Karnofsky Performance Scale

Table 47 Distribution of Memorial Delirium Assessment Scale scores at baseline and at Day 7

Table 48 Baseline clinical variables and association with Memorial Delirium Assessment Scale score over time

Table 49 Ordinary least squares regression serum anticholinergic activity and clinical variables at baseline

Chapter 6

Table 50 Comparative receptor antagonism of haloperidol and risperidone

Table 51 Studies exploring risperidone for the management of delirium

Table 52 Dosing for participants under 65 years

- Table 53 Dosing for participants over 65 years
- Table 54 Dosing of rescue medication for targeted symptoms
- Table 55 Post study treatments
- Table 56 Summary of study measures
- Table 57 Summary of study recruitment
- Table 58 Baseline characteristics of all randomised participants

List of figures

Chapter 1

Figure 1 Proposed mechanism of delirium and clinical conditions that may mediate delirium through this neurotransmitter system

Chapter 4

Figure 2 Patient flow for all participants of the main study and sub-study

Figure 3 Mean total calculated anticholinergic score at time-points leading to death

Figure 4 Mean total calculated anticholinergic score by three categories of prescribed medications at time-points leading to death

Figure 5 Associations with mean anticholinergic load and functional status by three categories of prescribed medications

Figure 6 Distribution of total length of inpatient stays

Figure 7 Association between health-service utilisation

Figure 8 Kaplan-Meier plot showing survival for the three categories of total anticholinergic score

Chapter 5

Figure 9 Schematic diagram of levels of central nervous system where glutamatergic, GABAergic, dopaminergic and cholinergic pathways interact and where psychoactive medications effects are potentially mediated (by medication class)

Figure 10 Serum anticholinergic activity competitive binding

Figure 11 Study flow diagram

Figure 12 Flow of participants from admission to palliative unit to participation in study

Figure 13 Box plot showing Memorial Delirium Assessment Scale total score on Day 0 by Australia-modified Karnofsky Performance Scale by three categories (n = 126)

Figure 14 Box plot showing serum anticholinergic activity on Day 0 by age group

Figure 15 Scatterplot of serum anticholinergic activity versus clinician rated anticholinergic load at baseline

Figure 16 Scatterplot and Lowess curve of MDAS vs SAA at baseline (Day 0)

Figure 17a Scatter plot of serum anticholinergic activity and oral morphine equivalents at baseline (Day 0)

Figure 17b Scatter plot of serum anticholinergic activity and oral diazepam equivalents at baseline

Figure 17c Scatter plot of serum anticholinergic activity and oral dexamethasone equivalents at baseline

Figure 18 Radar graph of mean Memorial Delirium Assessment Scale scores over 20 days for all participants

Figure 19 Radar graph of mean Memorial Delirium Assessment Scale scores over 20 days for participants who had either incident or prevalent delirium

- Figure 20 Predicted Memorial Delirium Assessment Scale values for model
- Figure 21a Australia-modified Karnofsky Performance Scale 20 and 30
- Figure 21b Australia-modified Karnofsky Performance Scale 40 and 50
- Figure 21c Australia-modified Karnofsky Performance Scale 60 and 70
- Figure 22a Memorial Delirium Assessment Scale cut-off for delirium of 10
- Figure 22b Memorial Delirium Assessment Scale cut-off for delirium of 7
- Figure 23 Receiver operator curve assessing predictive ability of baseline serum anticholinergic activity and occurrence of delirium
- Figure 24 Kaplan Meier plot showing survival by AKPS
- Figure 25 Kaplan Meier plot showing survival by age
- Figure 26 Kaplan Meier plot showing survival by serum anticholinergic activity

Chapter 6

- Figure 27 Study diagram
- Figure 28 Rescue dose diagram
- Figure 29 Project recruitment compared to actual recruitment

Glossary

α	Cronbach's alpha
κ	Cohen's kappa statistic
AA	Anticholinergic activity
ACB	Anticholinergic Burden Score
ACP	Aged care psychiatry
ACTRN	Australian and New Zealand Clinical Trials Registry number
AD	Alzheimer's disease
ADD	Assessment of Discomfort in Dementia protocol
ADL	Anticholinergic drug load Activities of daily living
AE	Adverse event
AIBL	Australian Imaging, Biomarkers and Lifestyle
AIN	Assistants in nursing
AKPS	Australia – modified Karnofsky Performance Status Scale
ARS	Anticholinergic Risk Scale
BD	Twice daily (<i>bis die</i>)
BOMC	Blessed Orientation Memory Concentration Cognitive Assessment
BUN	blood urea nitrogen
CAM	Confusion Assessment Method
CAM-ICU	Confusion Assessment Method – Intensive Care Unit
CCI	Charlson Comorbidity Index
CI	95% Confidence Interval
CIRS	Cumulative Illness Rating Scale
CNPI	Checklist of Nonverbal Pain Indicators

CNS	Central nervous system
CRAS	Clinician Rated Anticholinergic Scale (initial version)
CRAS-M	Clinician Rated Anticholinergic Scale – modified version
CSF	Cerebrospinal fluid
CT	Computerised Tomography
CTD	Cognitive Test for Delirium
DBI	Drug Burden Index
DEC	Delirium Etiology Checklist
DEQ	Delirium Experience Questionnaire
DI	Delirium Index
DMSS	Delirium Motor Subtype Scale
D-Pap	Delirium Palliative Prognostic Score
DRS	Delirium Rating Scale
DRS-R98	Delirium Rating Scale – Revised 98
DSI	Delirium Symptom Interview
DSM	Diagnostic and Statistical Manual
DSMB	Data Safety Monitoring Board
DSM III	Diagnostic and Statistical Manual of Mental Disorders, third edition
DSM-III-R	Diagnostic and Statistical Manual of Mental Disorders, third edition – revised
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders, fourth edition
DSM-IV-R	Diagnostic and Statistical Manual of Mental Disorders, fourth edition – revised
ECOG	European Cooperative Oncology Group
EDA	European Delirium Association
EEG	Electroencephalogram

ELISA	Enzyme-Linked Immunosorbent Assay
EORTC QLQ-C30	European Organization for Research and Treatment of Cancer- Quality of Life Questionnaire – core 30 questions
EPS	Extrapyramidal side effects
ESRS	Extrapyramidal Symptom Rating Scale
FACIT-Pal	Functional Assessment of Chronic Illness Therapy scale – Palliative care
FAM-CAM	Family Confusion Assessment Method
FSD	Full syndromal delirium
GABA	Gamma-aminobutyric acid
GCS	Glasgow Coma Scale
GEE	Generalised estimating equations
Gllamm	Generalised linear latent and mixed models
GP	General Practitioner
HC	Healthy controls
HELP	Hospital Elder Life Programme
HR	hazard ratio
HSCT	haematopoietic stem cell transplant
3H-QNB	tritiated quinuclidinyl benzilate
ICD	International Classification of Disease
ICD-10	International Classification of Disease version 10
ICU	Intensive care unit
ID	Identification number
IQCODE	Informant Questionnaire on Cognitive Decline in the elderly
ISRCTN	International standard randomised controlled trial number register
KPS	Karnofsky Performance Scale

LAR	Legally Authorised Representative
LHPA	Limbic-hypothalamic-pituitary-adrenal
MBP	Myelin Basic Protein
MCI	Mild Cognitive Impairment
MDAS	Memorial Delirium Assessment Scale
MMSE	Mini-Mental State Examination
MO	Medical oncology
MRC	Medical Research Council
MSAS	Memorial Symptom Assessment Scale
NICE	National Institute for Health and Clinical Excellence
nM	Nanomol
NOPPAIN	Non-Communicative Patients' Pain Assessment Instrument
NuDesc	Nursing Delirium Screening Scale
OR	Odds ratio
PACSLAC	Pain Assessment Checklist for Seniors with Limited Ability to Communicate
PADE	Pain Assessment for the Dementing Elderly scale
PAINAD	Pain Assessment in Advanced Dementia
PaP	Palliative Prognostic Score
PCT	Palliative Care Trial
PIM	Potentially Inappropriate Medications
prn	<i>Pro re nata</i> , as required or as needed
QT Interval	The relationship between two conduction points on an electrocardiograph (ECG)
QT _c	QT interval, corrected for heart rate
r	Spearman's rank correlation (rho)

RASS	Richmond Agitation Sedation Scale
RCT	Randomised controlled trial
ROC	Receiver operator curve
S100B	S100 calcium binding protein B
SAA	Serum anticholinergic activity
SAE	Serious adverse events
SAPS	Southern Adelaide Palliative Services
SC	Subcutaneous
SCARED	Stressful Caregiving Response to Experiences of Dying Questionnaire
SCID	Structured clinical interview for DSM-IV diagnoses
SD	Standard deviation
SE	Standard error
SPMSQ	Short Portable Mental Status Questionnaire
SSD	Subsyndromal delirium
START	Screening Tool to Alert doctors to Right Treatment
STOPP	Screening Tool of Older Persons' potentially inappropriate Prescriptions
UK	United Kingdom
US	United States
VTA	Ventral tegmental area

Abstract

Aim: Delirium in the palliative care population is a prevalent and distressing problem. To improve delirium recognition and management understanding of how clinical decisions are made for patients with a palliative diagnosis and delirium is crucial. Cholinergic mechanisms are considered important in the pathophysiology of delirium but has not been explored in the palliative population. This thesis aims to explore clinical decision-making in the management of delirium from medical and nursing perspectives, to understand the contribution of anticholinergic mechanisms in delirium pathophysiology and how these impact on outcomes, and to develop clinical trial designs which can assess net clinical benefit of delirium therapies in the palliative setting.

Methods: The thesis presents four distinct studies, and a clinical trial protocol with results to date. The first study utilises survey methodology to determine medical specialists' views on care location, investigations, and management of delirium in advanced cancer. In the second study, qualitative methods explored nurses' views on delirium symptoms, management choices, and their views on what caused distress for the person with delirium and their family. Anticholinergic medication use was mapped longitudinally to death, and associations with symptoms, quality of life, functional status and health-service utilisation were explored. The third study comprised serum anticholinergic activity on admission to an inpatient palliative care unit and its association with prevalent and incident delirium in palliative care patients with advanced cancer, after consideration of other demographic and aetiological factors. In the final study, a clinical trial compared the efficacy of risperidone, haloperidol and placebo in delirium in palliative care, discussing robust trial design to determine net clinical benefit of therapies for delirium.

Results: Significant variability in delirium care from both medical and nursing perspectives exists. Anticholinergic medication is predominantly symptom control medication associated with reduced function, dry mouth and difficulty concentrating, but not health-service utilisation nor survival. Delirium occurrence was not associated with anticholinergic medication or serum anticholinergic activity. Comorbid illness severity, benzodiazepine dose and presence of cerebral metastases on admission predicts delirium.

Implications: Some of the variability seen in clinical practice relates to an evidence practice gap with implications for translation of the delirium evidence base into practice; equally, there are some aspects of delirium care unique to the palliative population. Anticholinergic prescribing in palliative care has potential impacts on function, symptoms and quality of life; however, not on delirium occurrence. Vigilance is needed for the palliative patient with comorbid illness and cerebral metastases, as their chance of developing delirium is high. Well-designed and feasible randomised controlled trials can be conducted to evaluate delirium therapies, and this can also be achieved in the palliative population. Statistical methods need to adequately power the study, and account for delirium fluctuation and other factors influencing delirium outcomes. Standardised treatment algorithms and a contingency for participants whose symptoms escalate and safety or distress is an issue are important. Legislative frameworks can ensure balance of protection of those who lack decision-making capacity, with ethical proxy consent and advancement of the evidence base to improve delirium care.